Tue, 09 Jun 2020 00:00:00 -0400
Mon, 08 Jun 2020 00:00:00 -0400
Teva Pharmaceuticals USA, Inc. is voluntarily recalling fourteen (14) lots of Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, 100 and 1000 count bottles, in the United States to the consumer-level due to the detection of N-Nitrosodimethylamine (NDMA) levels in excess of the
Marksans Pharma Limited, India is voluntarily recalling Metformin Hydrochloride Extended-Release Tablets, USP 500mg, lot # XP9004, to the consumer level. FDA analysis has found the product to contain N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit (ADI) of 96ng/da
FDA warns lab staff that exposure to cyanide gas may result from a reaction between transport media and testing platforms that are not compatible.
FDA is notifying health care professionals about the temporary absence of the “paralyzing agent” warning statement embossed on the vial caps of two neuromuscular blocking agents.
According to the European Centre for Disease Prevention and Control, since 31 December 2019 to 8 May 2020 the SARS-CoV-2 pandemic led to more than 3.8 million infections and 269,068 deaths.1 There are conflicting assumptions about the possible adverse or protective effects of antihypertensive drugs acting on the renin-angiotensin-aldosterone (RAAS) system in patients with SARS-CoV-2.2-5 Given their common use, it is important to understand what evidence is available to support the various hypotheses.
Description of the two classes of drugs
80.211.154.110